Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Pàgina 1 des de 21 resultats
Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Intestinal adaptation has been studied in rats with pancreatic atrophy induced by feeding a copper-deficient diet and penicillamine and in rats with carbohydrate maldigestion induced by feeding of an alpha-glucosidase inhibitor (acarbose). Pancreatic atrophy led to a significant increase of weight,
Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BB/W-rat.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The effect of the alpha-glucosidase inhibitor acarbose on postprandial hyperglycaemia was explored in the spontaneously diabetic BB/W-rat. Acarbose-treatment (5 mg.kg body weight-1.day-1) of diabetic BB/W-rats maintained on small doses of insulin, was associated with a 40% reduction in the 24-h
Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The effect of acarbose, an alpha-glucosidase inhibitor, on glycaemic control, was compared with placebo in a double-blind, randomised, group comparison study during 16 weeks in 20 non-obese non-insulin dependent diabetic patients in whom sulphonylurea treatment had been withdrawn. There was
Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Oral administration of alpha-glucosidase inhibitor reduces postprandial serum glucose and insulin concentrations; thus, alpha-glucosidase inhibitor is used for the treatment of diabetes mellitus worldwide. In our study, we have evaluated the effect of alpha-glucosidase inhibitor, acarbose, on
Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Multiple oral therapies are required long term for the majority of patients with type 2 diabetes mellitus to achieve acceptable glycaemic levels; alternatively, insulin therapy has to be initiated. This study investigated the addition of acarbose to maximum doses of sulfonylurea in very
Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Postprandial hypotension (PPH) is a major clinical problem in patients with autonomic failure such as that observed in multiple system atrophy (MSA). The pathophysiology of PPH remains unclear, although autonomic dysfunction and gastrointestinal vasoactive peptides have been suspected to participate
Acarbose improves health and lifespan in aging HET3 mice.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
To follow-up on our previous report that acarbose (ACA), a drug that blocks postprandial glucose spikes, increases mouse lifespan, we studied ACA at three doses: 400, 1,000 (the original dose), and 2,500 ppm, using genetically heterogeneous mice at three sites. Each dose led to a significant change
Reduction of hepatorenal and pancreatic damage by Ferula elaeochytris extract in STZ induced diabetic rats.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The therapeutic potential and antioxidant capacity of Ferula elaeochytris extract (FE) in the liver, kidney and pancreas of rats with diabetes induced by streptozotocin (STZ) was assessed using biochemistry, histopathology and immunohistochemistry. Forty adult Wistar albino male rats were
The impact of pharmacotherapy on weight management in type 2 diabetes.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Today, obesity is the most important modifiable risk factor for type 2 diabetes. An excess of body fat is associated with a deterioration of glucose utilisation and promotes the development of type 2 diabetes, particularly in those with a genetic predisposition for the disease. It is also well
Antihyperglycaemic agents. Drug interactions of clinical importance.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension, dyslipidaemias, coronary insufficiency, heart failure and arthropathies. Thus, polymedication is the rule in this
Rosiglitazone.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Rosiglitazone, a thiazolidinedione antidiabetic agent, improves insulin resistance, a key underlying metabolic abnormality in most patients with type 2 (non-insulin-dependent) diabetes mellitus. In animal models of insulin resistance, rosiglitazone decreased plasma glucose, insulin and triglyceride
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Type 2 diabetes results from the abnormal resistance of peripheral tissues to insulin and from the progressive insulin secretory failure of the pancreatic beta-cells. Treatment of type 2 diabetes has greatly improved due to the availability of new classes of oral antidiabetic drugs (OADs) and new
[What is the most effective approach to the reduction of cardiovascular risk in type-2 diabetes mellitus?].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
It is well known that the target blood glucose values are not fulfilled in treatment of patients with type 2 diabetes mellitus. (UKPDS) The high mortality rate in type 2 diabetes mellitus is associated with the augmented cardiovascular risk. It is well documented, that the beneficial influence of
[Current principles of therapy of diabetes mellitus in old age].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The criteria for the diagnosis of diabetes are the same in all age groups. The main reason for a deterioration of glucose tolerance with age is insulin resistance, primarily concerning glucose uptake of skeletal muscle. The decision of if and how diabetes is treated in old people is a highly
Treatment for hyperglycemia promotes pancreatic regeneration in rats without CCK-1 receptor gene expression.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Recent studies have suggested that CCK is not essential for normal pancreatic growth in mice. We examined whether the treatment of hyperglycemia participates in a non-CCK-1-receptor-mediated mechanism of pancreatic regeneration after partial (30%) pancreatectomy (Px) with use of Otsuka
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
